4.93
-0.2(-3.90%)
Currency In USD
| Previous Close | 5.13 |
| Open | 5.18 |
| Day High | 5.19 |
| Day Low | 4.91 |
| 52-Week High | 66 |
| 52-Week Low | 4.11 |
| Volume | 152,331 |
| Average Volume | 123,090 |
| Market Cap | 15.74M |
| PE | -0.2 |
| EPS | -24.28 |
| Moving Average 50 Days | 5.02 |
| Moving Average 200 Days | 7.53 |
| Change | -0.2 |
If you invested $1000 in Cellectar Biosciences, Inc. (CLRB) 10 years ago, it would be worth $0.08 as of October 08, 2025 at a share price of $4.93. Whereas If you bought $1000 worth of Cellectar Biosciences, Inc. (CLRB) shares 5 years ago, it would be worth $12 as of October 08, 2025 at a share price of $4.93.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Cellectar Biosciences, Inc. Enters Into Agreements to Raise $5.8 Million
GlobeNewswire Inc.
Yesterday at 12:30 PM GMT
FLORHAM PARK, N.J., Oct. 07, 2025 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ:CLRB) (“Cellectar” or the “company”), a late-stage biotechnology company focused on the discovery and development of drugs for the treatment of cancer, today
Cellectar Biosciences Announces European Medicines Agency (EMA) Confirms Eligibility to File for Conditional Marketing Authorization (CMA) for Iopofosine I 131 as a Treatment for Refractory (post-BTKi) Waldenstrom Macroglobulinemia (WM)
GlobeNewswire Inc.
Oct 06, 2025 11:00 AM GMT
Following Scientific Advice and Guidance from Scientific Advice Working Party (SAWP) of EMA, Submission of CMA Application for Iopofosine I 131 as a Treatment for Refractory (post-BTKi) WM Expected in Early 2026 Potential 2027 European Approval and
Cellectar Biosciences Presented Compelling Data in Oral Session and Panel Discussions at the American Association for Cancer Research Special Conference on Discovery and Innovation in Pediatric Cancer
GlobeNewswire Inc.
Sep 30, 2025 12:30 PM GMT
CLOVER-2 Phase 1 Clinical Study Evaluating Iopofosine I 131 in Relapsed/Refractory Pediatric High-Grade Glioma Patients Showed Extended Progression-Free Survival and Overall SurvivalFLORHAM PARK, N.J., Sept. 30, 2025 (GLOBE NEWSWIRE) -- Cellectar B